A Phase 3 interventional study of Ibrutinib and Placebo in Waldenström's Macroglobulinemia, sponsored by Pharmacyclics LLC.. Completed at 48 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-03.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia — 2 open to participants now, 7 under way, 2 of them phase 3. ibrutinib · Waldenstrom Macroglobulinemia.
Among the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, this one is the 4th largest by enrollment, is one of 3 that started in 2014, is one of 4 in phase 3, and was the 7th registered.
524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 62 are open to participants now.
Browse Waldenstrom Macroglobulinemia studies →2 of the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia are open now, in 1 country. Recruiting first, the newest first:
University College, London · Sites in United Kingdom
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China
Ages 18–75
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 48 Waldenstrom Macroglobulinemia studies recruiting now, 44 (92%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 5 · Phase 4 1
First in 2009; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 181 is above the median of 39 across 429 interventional studies indexed under Waldenstrom Macroglobulinemia.
Median enrollment 48 across the 25 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
AbbVie has 6 studies filed under Waldenstrom Macroglobulinemia — fewer than ten, so there is no comparison to draw.
2 of the studies testing ibrutinib in Waldenstrom Macroglobulinemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination with rituximab in participants with Waldenström's macroglobulinemia (WM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligibility Criteria for the Randomized Study
Inclusion Criteria:
Exclusion Criteria:
Disease that is to the last prior rituximab-containing therapy defined as either
Eligibility Criteria for Open-label Substudy Treatment Arm C
The inclusion/exclusion criteria for the substudy (Arm C) are identical to those described above for the randomized study but, to be eligible, subjects need to be considered refractory to the last prior rituximab-containing therapy defined as either
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ibrutinib: 420 mg (3 capsules x 140 mg) orally administered daily beginning from Day 1. Rituximab: 375 mg/m\^2 intravenous (IV) per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
Drug: Ibrutinib · Drug: Rituximab
Placebo: 3 capsules of placebo orally administered daily beginning from Day 1. Rituximab: 375 mg/m\^2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
Drug: Placebo · Drug: Rituximab
Ibrutinib: 420 mg (3 capsules) orally administered daily beginning from Day 1.
Drug: Ibrutinib
Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54
PFS was defined as the time from date randomization to date of first IRC-confirmed disease progression (PD) assessed according to the modified VIth International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria (National Comprehensive Cancer Network \[NCCN\] 2014) or death due to any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. As the median PFS was not reached in the Ibrutinib + Rituximab arm at the time of the analysis, Kaplan Meier landmark estimate of the PFS rate at 54 months (that is, the estimated percentage of participants with PFS at Month 54) is presented.
Time frame: Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])
Overall Response Rate (ORR) Based on IRC Assessment Up to 3 Years After Last Participant Randomized
ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), very good partial response (VGPR), or partial response (PR) per the IRC assessment at or prior to initiation of subsequent antineoplastic therapy and confirmed by 2 consecutive assessments. IRC assessment of response was conducted according to the modified VIth IWWM (NCCN 2014) criteria and incorporated assessments from the central radiology review. CR required complete resolution of lymphadenopathy/splenomegaly if present at baseline. VGPR and PR required reduction in lymphadenopathy/splenomegaly if present at baseline.. Kaplan-Meier estimate.
Time frame: Median time on study: 49.7 months (Ibr+R and Pbo+R) and 57.9 months (Open-Label Ibr)
Time to Next Treatment (TnT) Time From the Date of Randomization to the Start Date of Any Subsequent WM Treatment.
TTnT was measured from the date of randomization to the start date of any subsequent WM treatment. Participants without subsequent treatment were censored at the date of the last study visit. As the median TTnT was not reached in the Ibrutinib + Rituximab arm and the Open-Label Substudy arm at the time of the analysis, Kaplan Meier landmark estimate of the TTnT rate at 54 months (that is, the estimated percentage of participants not receiving subsequent WM treatment at Month 54) are presented.
Time frame: Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])
Percentage of Participants With Sustained Hemoglobin (Hgb) Improvement Up to 3 Years After Last Participant Randomized
Percentage of participants achieving a sustained improvement in Hgb at or prior to initiation of subsequent antineoplastic therapy. Hgb improvement is defined as an increase of ≥ 2 g/dL over baseline regardless of baseline value, or an increase to \>11 g/dL with a ≥0.5 g/dL improvement if baseline is ≤ 11 g/dL. Sustained Hgb improvement is defined as improvement that is sustained continuously for ≥ 56 days (8 weeks) without blood transfusion or growth factors, which includes hemoglobin \> 110 g/L with at least a 5 g/L improvement if baseline ≤110 g/L or increase ≥20 g/L over baseline.
Time frame: Median time on study: 49.7 months (Ibr+R and Pbo+R) and 57.9 months (Open-Label Ibr)
Percentage of Participants With ≥ 3 Points Increase From Baseline by Week 25 in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Subscale Score
Percentage of participants with ≥ 3 points increase from baseline by Week 25 in the FACIT-Fatigue subscale score.The FACIT-Fatigue is a 13-item questionnaire that assesses participant reported fatigue and its impact upon daily activities and function over the past 7 days. Each of the 13 items of the FACIT-Fatigue Scale ranges from 0-4, with a range of possible total scores from 0 (extreme fatigue) to 52 (no fatigue). Scores below 30 indicate severe fatigue.
Time frame: Baseline, 25 weeks
Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 54
OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive. As the median OS was not reached in any treatment arm at the time of the analysis, Kaplan Meier point estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 54) are presented.
Time frame: Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])
This study was conducted in 48 sites (10 in the United States, 30 in Europe, 4 in Canada and 4 in Australia).
| Milestone | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib |
|---|---|---|---|
| Started | 75 | 75 | 31 |
| Completed | 61 | 56 | 21 |
| Not completed | 14 | 19 | 10 |
| Withdrew: Death | 7 | 10 | 8 |
| Withdrew: Lost to follow-up | 1 | 3 | 0 |
| Withdrew: Withdrawal by subject | 6 | 6 | 1 |
| Withdrew: Other, not specified | 0 | 0 | 1 |
PFS was defined as the time from date randomization to date of first IRC-confirmed disease progression (PD) assessed according to the modified VIth International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria (National Comprehensive Cancer Network \[NCCN\] 2014) or death due to any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. As the median PFS was not reached in the Ibrutinib + Rituximab arm at the time of the analysis, Kaplan Meier landmark estimate of the PFS rate at 54 months (that is, the estimated percentage of participants with PFS at Month 54) is presented.
| percentage of participants | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib |
|---|---|---|---|
| Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54 | 68.0 (54.8 to 78.1) | 25.3 (15.3 to 36.6) | 39.7 (22.3 to 56.7) |
ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), very good partial response (VGPR), or partial response (PR) per the IRC assessment at or prior to initiation of subsequent antineoplastic therapy and confirmed by 2 consecutive assessments. IRC assessment of response was conducted according to the modified VIth IWWM (NCCN 2014) criteria and incorporated assessments from the central radiology review. CR required complete resolution of lymphadenopathy/splenomegaly if present at baseline. VGPR and PR required reduction in lymphadenopathy/splenomegaly if present at baseline.. Kaplan-Meier estimate.
| percentage of participants | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib |
|---|---|---|---|
| Overall Response Rate (ORR) Based on IRC Assessment Up to 3 Years After Last Participant Randomized | 76.0 | 30.7 | 77.4 |
TTnT was measured from the date of randomization to the start date of any subsequent WM treatment. Participants without subsequent treatment were censored at the date of the last study visit. As the median TTnT was not reached in the Ibrutinib + Rituximab arm and the Open-Label Substudy arm at the time of the analysis, Kaplan Meier landmark estimate of the TTnT rate at 54 months (that is, the estimated percentage of participants not receiving subsequent WM treatment at Month 54) are presented.
| percentage of participants | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib |
|---|---|---|---|
| Time to Next Treatment (TnT) Time From the Date of Randomization to the Start Date of Any Subsequent WM Treatment. | 87.4 (77.2 to 93.3) | 29.4 (18.2 to 41.6) | 64.6 (44.1 to 79.2) |
Percentage of participants achieving a sustained improvement in Hgb at or prior to initiation of subsequent antineoplastic therapy. Hgb improvement is defined as an increase of ≥ 2 g/dL over baseline regardless of baseline value, or an increase to \>11 g/dL with a ≥0.5 g/dL improvement if baseline is ≤ 11 g/dL. Sustained Hgb improvement is defined as improvement that is sustained continuously for ≥ 56 days (8 weeks) without blood transfusion or growth factors, which includes hemoglobin \> 110 g/L with at least a 5 g/L improvement if baseline ≤110 g/L or increase ≥20 g/L over baseline.
| percentage of participants | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib |
|---|---|---|---|
| Percentage of Participants With Sustained Hemoglobin (Hgb) Improvement Up to 3 Years After Last Participant Randomized | 77.3 | 42.7 | 71.0 |
Percentage of participants with ≥ 3 points increase from baseline by Week 25 in the FACIT-Fatigue subscale score.The FACIT-Fatigue is a 13-item questionnaire that assesses participant reported fatigue and its impact upon daily activities and function over the past 7 days. Each of the 13 items of the FACIT-Fatigue Scale ranges from 0-4, with a range of possible total scores from 0 (extreme fatigue) to 52 (no fatigue). Scores below 30 indicate severe fatigue.
| percentage of participants | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib |
|---|---|---|---|
| Percentage of Participants With ≥ 3 Points Increase From Baseline by Week 25 in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Subscale Score | 68.0 | 54.7 | 87.1 |
OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive. As the median OS was not reached in any treatment arm at the time of the analysis, Kaplan Meier point estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 54) are presented.
| percentage of participants | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib |
|---|---|---|---|
| Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 54 | 86.4 (73.7 to 93.3) | 84.2 (71.3 to 91.6) | 73.4 (53.7 to 85.7) |
Collected over From first dose of study drug up to 30 days after the last dose of study drug. Median duration of treatment was 47.7 months for the Ibr+R arm, 15.5 months for the Pbo+R arm, and 40.7 months for the Open-Label Ibr arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibrutinib + Rituximab | 9/75 (12%) | 40/75 (53.3%) | 75/75 (100%) |
| Placebo + Rituximab | 10/75 (13.3%) | 25/75 (33.3%) | 75/75 (100%) |
| Open-Label Substudy: Ibrutinib | 8/31 (25.8%) | 16/31 (51.6%) | 30/31 (96.8%) |
| Event | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 8/75 | 1/75 | 0/31 |
| PneumoniaInfections and infestations | 8/75 | 2/75 | 1/31 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/75 | 5/75 | 0/31 |
| SyncopeNervous system disorders | 1/75 | 0/75 | 2/31 |
| Respiratory tract infectionInfections and infestations | 4/75 | 0/75 | 1/31 |
| FallInjury, poisoning and procedural complications | 3/75 | 0/75 | 0/31 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/75 | 0/75 | 0/31 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/75 | 0/75 | 1/31 |
| NeutropeniaBlood and lymphatic system disorders | 0/75 | 0/75 | 1/31 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/75 | 0/75 | 1/31 |
| Event | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib |
|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 32/75 | 43/75 | 0/31 |
| Tumour flareNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/75 | 35/75 | 0/31 |
| DiarrhoeaGastrointestinal disorders | 23/75 | 11/75 | 14/31 |
| PyrexiaGeneral disorders | 12/75 | 12/75 | 11/31 |
| NeutropeniaBlood and lymphatic system disorders | 12/75 | 7/75 | 9/31 |
| Back painMusculoskeletal and connective tissue disorders | 13/75 | 7/75 | 9/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/75 | 8/75 | 9/31 |
| AnaemiaBlood and lymphatic system disorders | 17/75 | 21/75 | 5/31 |
| Increased tendency to bruiseBlood and lymphatic system disorders | 9/75 | 2/75 | 8/31 |
| HypertensionVascular disorders | 18/75 | 3/75 | 8/31 |
| Age, Customized(Participants) | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib | Total |
|---|---|---|---|---|
| < 65 years old | 28 | 30 | 14 | 72 |
| >= 65 years old | 47 | 45 | 17 | 109 |
| Sex: Female, Male(Participants) | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib | Total |
|---|---|---|---|---|
| Female | 30 | 21 | 11 | 62 |
| Male | 45 | 54 | 20 | 119 |
| Ethnicity (NIH/OMB)(Participants) | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 1 | 5 |
| Not Hispanic or Latino | 72 | 74 | 30 | 176 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ibrutinib + Rituximab | Placebo + Rituximab | Open-Label Substudy: Ibrutinib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 3 | 0 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 2 |
| White | 58 | 60 | 26 | 144 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 13 | 14 | 3 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at the following link.
Data sharing details ↗ · yoda.yale.edu
Ran from Jul 2014 to primary completion in Nov 2019, 64 months.
Results were first posted in Nov 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibrutinib · Rituximab
Waldenstrom Macroglobulinemia →